Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $79.8571.

A number of research firms have recently commented on TARS. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Wednesday, October 8th. Zacks Research upgraded shares of Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $51.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 6th. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, HC Wainwright lifted their target price on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the company a “neutral” rating in a report on Monday, October 20th.

Tarsus Pharmaceuticals Price Performance

Shares of NASDAQ:TARS opened at $80.77 on Friday. The company has a quick ratio of 4.25, a current ratio of 4.29 and a debt-to-equity ratio of 0.22. The company has a market cap of $3.43 billion, a P/E ratio of -39.99, a PEG ratio of 1.37 and a beta of 0.59. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $85.25. The company has a 50-day moving average price of $77.40 and a 200 day moving average price of $60.85.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 22.17% and a negative return on equity of 26.29%. The firm had revenue of $118.70 million during the quarter, compared to the consensus estimate of $114.22 million. Research analysts predict that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

Insider Activity

In related news, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the sale, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider owned 38,958 shares in the company, valued at $3,120,535.80. The trade was a 15.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after purchasing an additional 339 shares during the period. Osaic Holdings Inc. lifted its holdings in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after purchasing an additional 2,462 shares during the period. Tower Research Capital LLC TRC grew its position in Tarsus Pharmaceuticals by 220.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after buying an additional 2,782 shares in the last quarter. West Wealth Group LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at about $202,000. Finally, Valeo Financial Advisors LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $209,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.